0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Tobacco Use and Oral HPV-16 Infection FREE

Carole Fakhry, MD, MPH1; Maura L. Gillison, MD, PhD2; Gypsyamber D’Souza, PhD, MS, MPH3
[+] Author Affiliations
1Johns Hopkins University School of Medicine, Baltimore, Maryland
2Ohio State University Comprehensive Cancer Center, Columbus
3Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
JAMA. 2014;312(14):1465-1467. doi:10.1001/jama.2014.13183.
Text Size: A A A
Published online

Oral human papillomavirus type 16 (HPV-16), a sexually transmitted infection, is believed to be responsible for the increase in incidence of oropharyngeal squamous cell cancers in the United States.1 An association between self-reported number of cigarettes currently smoked per day and oral HPV prevalence has been observed.2,3 We investigated associations between objective biomarkers reflective of all current tobacco exposures (environmental, smoking, and use of smokeless tobacco) and oral HPV-16 prevalence.

The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, stratified multistage probability sample of the US population.4 The NHANES was approved by the National Center for Health Statistics institutional review board and written informed consent was obtained from participants. During 2009-2012, the response rate was 73.4%. Mobile examination center participants aged 14 to 69 years were eligible for oral HPV DNA testing. Exfoliated oral cells were collected using a 30-second oral rinse and gargle, and tested for HPV-16 as previously reported.2

Computer-assisted self-interviews were used to ascertain self-reported tobacco use and sexual behaviors. Self-reported tobacco use for the past 5 days included any nicotine-containing product. Biomarkers of recent tobacco use included serum cotinine, a major nicotine metabolite, and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a tobacco-specific, carcinogenic metabolite.4

Of 20 293 participants interviewed, the analysis was restricted to participants aged 18 to 59 years (n = 8527) with data on oral HPV-16 and recent tobacco use (n = 6887). The principal outcome was oral HPV-16 infection. NHANES sample weights were used to estimate prevalence. Mean biomarker values were compared using Wald tests. For modeling, cotinine and NNAL were log-transformed and considered as continuous and categorical variables. The association of tobacco use with oral HPV-16 was explored using logistic regression. All multivariable models included variables considered significant (2-sided P < .05) in bivariable analysis and important factors based on the literature.2 Analyses were performed using SUDAAN software version 11.0.1 (RTI International).

Among 6887 participants, 2012 (28.6%; 95% CI, 26.5%-30.9%) were current tobacco users and 63 (1.0%; 95% CI, 0.8%-1.3%) had oral HPV-16 detected. Current tobacco users were more likely than nonusers to be male, younger, less educated, and to have a higher number of lifetime oral sexual partners (Table 1). In bivariable analysis, self-reported and biological measures of tobacco exposure as well as oral sexual behavior were significantly associated with prevalent oral HPV-16 infection (Table 2). Oral HPV-16 prevalence was greater in current tobacco users (2.0%; 95% CI, 1.3%-3.1%) compared with never or former tobacco users (0.6%; 95% CI, 0.4%-0.9%) (P = .004). Mean cotinine (157.7 ng/mL vs 57.2 ng/mL, P = .002) and NNAL levels (0.36 ng/mL vs 0.12 ng/mL, P = .02) were higher in individuals with vs without oral HPV-16 infection.

Table Graphic Jump LocationTable 1.  Description of NHANES Study Population Included in Analysis by Current Self-reported Tobacco Usea
Table Graphic Jump LocationTable 2.  Bivariable and Multivariable Associations of Biomarkers and Behavioral Measures of Current Tobacco Use With Oral HPV-16

All biomarkers of tobacco exposure remained associated with oral HPV-16 infection after adjustment for other factors (Table 2). Significant dose-response relationships were observed between cotinine (P = .02 for trend) or NNAL (P = .01 for trend) levels and odds of oral HPV-16 infection (Table 2). Each log increase in cotinine, approximating 3 cigarettes per day, was independently associated with oral HPV-16 prevalence (adjusted odds ratio, 1.31; 95% CI, 1.07-1.60). Each log increase in NNAL, approximating 4 cigarettes per day, was independently associated with oral HPV-16 prevalence (adjusted odds ratio, 1.68; 95% CI, 1.23-2.28).

In this large cross-sectional, population-based study, we demonstrated statistically significant dose-response relationships between behavioral and objective biomarkers of current tobacco use and oral HPV-16 infection. Tobacco use is an established co-factor for the development of cervical cancer, for which HPV infection is a necessary cause.5 Tobacco use has local and systemic immunosuppressive effects6; however, the specific biological mechanisms underlying our observed associations are unknown. Tobacco use may alter determinants of oral HPV-16 prevalence, such as incidence, persistence, or reactivation of infection.

These findings highlight the need to evaluate the role of tobacco in the natural history of oral HPV-16 infection and progression to malignancy. Although adjusted for sexual behavior, we cannot entirely exclude the possibility that tobacco use is a marker for risky behavior. Additional limitations include some unstable estimates and a cross-sectional study design that precludes our ability to determine temporality or causation.

Section Editor: Jody W. Zylke, MD, Senior Editor.

Corresponding Authors: Gypsyamber D’Souza, PhD, MS, MPH, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205 (gdsouza2@jhu.edu); and Carole Fakhry, MD, MPH (cfakhry@jhmi.edu).

Author Contributions: Dr D’Souza had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Fakhry, D’Souza.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Fakhry, D’Souza.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Fakhry, D’Souza.

Obtained funding: All authors.

Administrative, technical, or material support: Fakhry, D’Souza.

Study supervision: Fakhry, D’Souza.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Gillison and D’Souza reported receiving previous research support from Merck Inc. Dr Gillison also reported serving as an unpaid consultant to GlaxoSmithKline. No other disclosures were reported.

Funding/Support: This study was supported by grants P50DE019032, R01DE021395, R01DE023175 from the National Institute of Dental and Craniofacial Research and funding from the Milton J. Dance Head and Neck Center and Merck.

Role of the Funder/Sponsor: The National Institute of Dental and Craniofacial Research, the Milton J. Dance Head and Neck Center, and Merck had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Timothy S. McNeel, BA (Information Management Services Inc), assisted with statistical analyses and received compensation.

Chaturvedi  AK, Engels  EA, Pfeiffer  RM,  et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
PubMed   |  Link to Article
Gillison  ML, Broutian  T, Pickard  RK,  et al.  Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693-703.
PubMed   |  Link to Article
Chaturvedi  AK, Graubard  BI, Pickard  RK, Xiao  W, Gillison  ML.  High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis. 2014;210(3):441-447.
PubMed   |  Link to Article
US Centers for Disease Control and Prevention. 2009-2010 and 2011-2012 National Health and Nutrition Examination Survey data.http://www.cdc.gov/nchs/nhanes.htm. Accessibility verified September 15, 2014.
Bosch  FX, de Sanjosé  S.  The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23(4):213-227.
PubMed   |  Link to Article
Sopori  M.  Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372-377.
PubMed   |  Link to Article

Figures

Tables

Table Graphic Jump LocationTable 1.  Description of NHANES Study Population Included in Analysis by Current Self-reported Tobacco Usea
Table Graphic Jump LocationTable 2.  Bivariable and Multivariable Associations of Biomarkers and Behavioral Measures of Current Tobacco Use With Oral HPV-16

References

Chaturvedi  AK, Engels  EA, Pfeiffer  RM,  et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
PubMed   |  Link to Article
Gillison  ML, Broutian  T, Pickard  RK,  et al.  Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693-703.
PubMed   |  Link to Article
Chaturvedi  AK, Graubard  BI, Pickard  RK, Xiao  W, Gillison  ML.  High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis. 2014;210(3):441-447.
PubMed   |  Link to Article
US Centers for Disease Control and Prevention. 2009-2010 and 2011-2012 National Health and Nutrition Examination Survey data.http://www.cdc.gov/nchs/nhanes.htm. Accessibility verified September 15, 2014.
Bosch  FX, de Sanjosé  S.  The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23(4):213-227.
PubMed   |  Link to Article
Sopori  M.  Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372-377.
PubMed   |  Link to Article
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

3,662 Views
10 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: What Can the Medical History and Physical Examination Tell Us About Low Back Pain?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Is There Evidence of Systemic Disease?